Moderna, Inc. — Director's Dealing 2023

Sep 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-09-13

Reporting Person: AFEYAN NOUBAR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-13	Common Stock	S	4281	$108.2059	Disposed	2232650	Direct
2023-09-13	Common Stock	S	4174	$108.7667	Disposed	2228476	Direct
2023-09-13	Common Stock	S	1400	$110.2593	Disposed	2227076	Direct
2023-09-13	Common Stock	S	3895	$111.2306	Disposed	2223181	Direct
2023-09-13	Common Stock	S	900	$112.1744	Disposed	2222281	Direct
2023-09-13	Common Stock	S	250	$113.22	Disposed	2222031	Direct
2023-09-13	Common Stock	S	100	$114.32	Disposed	2221931	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9662114	Indirect
Common Stock	3924	Indirect

Footnotes

F1: These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2023.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.57 to $108.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: Includes shares received in distributions-in-kind from Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") made prior to the filing of this report in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.57 to $109.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.71 to $110.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.74 to $111.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.83 to $112.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.83 to $113.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9: 8,100,794 shares are held directly by Flagship Fund IV and 1,561,320 shares are held directly by Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F10: 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.